10.1016/j.brs.2019.07.004 44
In GLUTag cells, DCA-stimulated GLP-1 secretion was significantly inhibited by H-89, a PKA inhibitor, and/or ESI-09, inhibitors of EPAC1, and EPAC2, in the low-glucose (0.1 mM) state (Fig
PMID: 29211849
Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label
Patients considering or taking GLP-1 medications should understand that whilst these drugs offer proven benefits for diabetes and weight management, any effects on acne are likely indirect and related to the metabolic and hormonal changes that accompany weight loss and improved insulin sensitivity, rather than a specific therapeutic action on acne itself
doi: 10.1016/j.cell.2020.11.009